Invitrogen, AB postpone merger
Thursday, 16 October, 2008
The merger between scientific equipment giants Invitrogen and Applied Biosystems has been delayed due to the slumping global market.
Shareholders had been scheduled to meet today to vote to finalise the merger.
But the deal, which was originally worth around US$7 billion, has been devalued to US$5.5 billion due to the sharp decline in the value of Invitrogen shares due to the stock market crisis.
In a joint statement, the two companies said there were also tax issues to be overcome before the merger goes ahead, which both are confident will happen.
The proposal will be discussed at a general meeting on October 28. Both companies expect the deal to go ahead as planned, and be complete by the end of November.
Antimicrobial resistance in children rises globally — 100K+ samples reveal
Spanning 82 countries, there was an increase in every region between 2004 and 2022, with the...
Robotic laboratory to fast-track drug invention, trials and commercialisation
The lab will house an automated system for high-throughput X-ray crystallography, often referred...
Bio-inspired robotic bird has stable flight in its sights
The nankeen kestrel is among the most stable fliers in the avian world. Using motion capture...
